Key result
Mogamulizumab immunotherapy is linked to acute myocarditis and heart failure that recurs upon rechallenge.
Why the study?
Mogamulizumab-associated myocarditis and heart failure in patients with T-cell lymphoma is a rare and clinically significant complication.
Mogamulizumab immunotherapy can be associated with acute myocarditis and heart failure, which may recur upon rechallenge.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for mogamulizumab myocarditis; prospective studies needed before monitoring or risk assessment changes.
A 62-year-old woman with human T-lymphotropic virus type 1 cell lymphoma developed heart failure after mogamulizumab, an immunotherapy agent. Clinical presentation and cardiac magnetic resonance imaging were consistent with myocarditis, and a recurrence of heart failure occurred after rechallenge with the therapy. (Level of Difficulty: Advanced.)
No takes yet. Share an insight, caveat, or question.
Kwan et al. (2021) studied this question. Mogamulizumab immunotherapy was associated with acute myocarditis and heart failure that recurred upon rechallenge in a patient with T-cell lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: